Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1187576 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Other | ||||
| SRR31411100_1.fastq.gz | Fastqsanger.gz | |||
| SRR31411100_2.fastq.gz | Fastqsanger.gz | |||
| SRR31411101_1.fastq.gz | Fastqsanger.gz | |||
| SRR31411101_2.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 249 |
Similar Datasets
Project description:An international standardization program towards the application of gene expression profiling in routine leukaemia diagnostics: The MILE study pre-phase. A total of 11 laboratories from three continents performed 204 analyses using a whole-genome expression microarray. In an effort to standardize the microarray procedure, each participating centre was equipped with identical hardware, software, and reagents. Designated study operators received intensive individual training on the sample preparation protocol. Experiment Overall Design: This study is part of the MILE Study (Microarray Innovations In LEukemia) program, headed by the European Leukaemia Network (ELN) and sponsored by Roche Molecular Systems, Inc. Experiment Overall Design: Each laboratory prepared two separate cell line total RNA samples, as well as three replicate leukaemia patient lysates in two distinct project stages: (i) a five-day course of protocol training, and (ii) independent proficiency testing. Experiment Overall Design: Using unsupervised, supervised, and r² correlation analyses we demonstrated that microarray analysis can be performed not only with remarkably high intra-laboratory reproducibility but also with comparable quality and reliability between eleven distinct laboratories.
2008-10-21 | E-GEOD-11135 | biostudies-arrayexpress
Project description:To support quantitative data analysis, we have developed a software, peakfit, that fits acquired chromatographic data to the log-normal peak equation and reports the calculated peak parameters. To demonstrate the capabilities of this approach, we provide hereby four example datasets: (1) 15 QCs of a PRM assay targeting the three most common isoforms of Apolipoprotein E (E2, E3, and E4); (2) PRM data of samples with 6 different ApoE phenotypes (E2/2, E2/3, E2/4, E3/3, E3/4, and E4/4); (3) shotgun run of a commercial HeLa digest to demonstrate processing of MS1 data, and (4) a quality control peptide mix to demonstrate assessment of chromatographic performance on basis of the base peak chromatogram.
2021-07-26 | PXD026875 | Pride
Project description:Cerebrovascular dysfunction is a hallmark feature of Alzheimer's disease (AD). One of the greatest risk factor for AD is the apolipoprotein E4 (E4) allele. APOE4 genotype has been shown to negatively impact on perivascular amyloid clearance, however, its direct influence along with the other APOE variants (APOE2 and APOE3) on the molecular integrity of the cerebrovasculature has not been largely explored. To address this, we employed a 10-plex tandem isobaric mass tag approach in combination with an ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method, to interrogate unbiased proteomic changes in cerebrovessels from AD and healthy control brains on different APOE genotype backgrounds. We first interrogated changes between healthy control homozygote E2/E2, E3/E3 and E4/E4 cases to identify underlying genotype specific effects on cerebrovessels. EIF2 signaling, regulation of eIF4 and 70S6K signaling and mTOR signaling were the top significantly altered pathways in E4/E4 compared to E3/E3 cases. EIF2, nitric oxide and sirtuin signaling pathways were the top significantly altered pathways in E4/E4 compared to E2/E2 cases. We used a Two-way ANOVA analysis to identify AD-dependent changes and their interactions with APOE genotype. The highest number of significantly regulated proteins from this interaction was observed in E3/E4 (192) and E4/E4 (189) cases. As above, EIF2, mTOR signaling and eIF4 and 70S6K signaling were the top three significantly altered pathways in E4 allele carriers (i.e. E3/E4 and E4/E4 genotypes). Of all the cerebrovascular cell specific markers identified in our proteomic analyses, endothelial cell, astrocyte, and smooth muscle cell specific protein markers were significantly altered in E4/E4 cases, while endothelial cells and astrocyte specific protein markers were altered in E3/E4 cases. These proteomic changes provide novel insights to explain the longstanding link between APOE4 and cerebrovascular dysfunction. The early and converging APOE4 dependent changes we identified could provide novel targets in the cerebrovasculature for developing disease modifying strategies to mitigate the effects of APOE4 genotype on increasing the risk for, and the path towards AD pathogenesis.
2021-03-23 | PXD023340 | Pride
Project description:This dataset contains 9 Illumina array spots representing 3 different treatment conditions of human mesenchymal cells. First two conditions in quadruplicate and third condition on single array. The data are intended to support blima package as testing data included in blimaTestingData package available at https://bitbucket.org/kulvait/blima page. The package was developed to make analysis of Illumina bead level data possible without summarizing them to the level of probes prior to differential expression testing. We label the arrays used for downstream analysis A1, A2, A3, A4 for condition A (cells grown in alfa-MEM medium with 10% fetal bovine serum) and E1, E2, E3, E4 for condition E (cells grown in CellGro medium, with human serum and suplements FGF-2, EGF, M-CSF and insulin) in the set there is also included array labeled D4 for condition D (cells grown in CellGro medium, with human serum and supplements PDGF-BB, EGF, M-CSF and insulin).
2014-03-24 | E-GEOD-56129 | biostudies-arrayexpress